Literature DB >> 22951893

Nucleic acid aptamers: an emerging frontier in cancer therapy.

Guizhi Zhu1, Mao Ye, Michael J Donovan, Erqun Song, Zilong Zhao, Weihong Tan.   

Abstract

The last two decades have witnessed the development and application of nucleic acid aptamers in a variety of fields, including target analysis, disease therapy, and molecular and cellular engineering. The efficient and widely applicable aptamer selection, reproducible chemical synthesis and modification, generally impressive target binding selectivity and affinity, relatively rapid tissue penetration, low immunogenicity, and rapid systemic clearance make aptamers ideal recognition elements for use as therapeutics or for in vivo delivery of therapeutics. In this feature article, we discuss the development and biomedical application of nucleic acid aptamers, with emphasis on cancer cell aptamer isolation, targeted cancer therapy, oncology biomarker identification and drug discovery.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22951893      PMCID: PMC3869973          DOI: 10.1039/c2cc35042d

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN: 1359-7345            Impact factor:   6.222


  109 in total

1.  Development of DNA aptamers using Cell-SELEX.

Authors:  Kwame Sefah; Dihua Shangguan; Xiangling Xiong; Meghan B O'Donoghue; Weihong Tan
Journal:  Nat Protoc       Date:  2010-06-03       Impact factor: 13.491

2.  ADLOC: an aptamer-displacement assay based on luminescent oxygen channeling.

Authors:  Björn Niebel; Christian Lentz; Monika Pofahl; Günter Mayer; Achim Hoerauf; Kenneth M Pfarr; Michael Famulok
Journal:  Chemistry       Date:  2010-09-24       Impact factor: 5.236

3.  Aptamer displacement identifies alternative small-molecule target sites that escape viral resistance.

Authors:  Satoko Yamazaki; Lu Tan; Günter Mayer; Jörg S Hartig; Jin-Na Song; Sandra Reuter; Tobias Restle; Sandra D Laufer; Dina Grohmann; Hans-Georg Kräusslich; Jürgen Bajorath; Michael Famulok
Journal:  Chem Biol       Date:  2007-07

4.  Crystal structure of an RNA aptamer bound to thrombin.

Authors:  Stephen B Long; Meredith B Long; Rebekah R White; Bruce A Sullenger
Journal:  RNA       Date:  2008-10-29       Impact factor: 4.942

5.  Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function.

Authors:  J Ishizaki; J R Nevins; B A Sullenger
Journal:  Nat Med       Date:  1996-12       Impact factor: 53.440

6.  Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors:  James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2006-06-25       Impact factor: 54.908

7.  Bi-specific aptamers mediating tumor cell lysis.

Authors:  Achim Boltz; Birgit Piater; Lars Toleikis; Ralf Guenther; Harald Kolmar; Bjoern Hock
Journal:  J Biol Chem       Date:  2011-04-29       Impact factor: 5.157

8.  The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells.

Authors:  Sridharan Soundararajan; Weiwei Chen; Eleanor K Spicer; Nigel Courtenay-Luck; Daniel J Fernandes
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

9.  Silencing of PTK7 in colon cancer cells: caspase-10-dependent apoptosis via mitochondrial pathway.

Authors:  Ling Meng; Kwame Sefah; Meghan B O'Donoghue; Guizhi Zhu; Dihua Shangguan; Afshan Noorali; Yan Chen; Lei Zhou; Weihong Tan
Journal:  PLoS One       Date:  2010-11-16       Impact factor: 3.240

10.  Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.

Authors:  Jiehua Zhou; Haitang Li; Shirley Li; John Zaia; John J Rossi
Journal:  Mol Ther       Date:  2008-05-06       Impact factor: 11.454

View more
  41 in total

Review 1.  Analysis of In Vitro Aptamer Selection Parameters.

Authors:  Maureen McKeague; Erin M McConnell; Jose Cruz-Toledo; Elyse D Bernard; Amanda Pach; Emily Mastronardi; Xueru Zhang; Michael Beking; Tariq Francis; Amanda Giamberardino; Ashley Cabecinha; Annamaria Ruscito; Rocio Aranda-Rodriguez; Michel Dumontier; Maria C DeRosa
Journal:  J Mol Evol       Date:  2015-11-03       Impact factor: 2.395

Review 2.  Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents.

Authors:  Khaled S Allemailem; Ahmad Almatroudi; Mohammed A Alsahli; Ghaiyda Talal Basfar; Faris Alrumaihi; Arshad Husain Rahmani; Amjad Ali Khan
Journal:  3 Biotech       Date:  2020-11-24       Impact factor: 2.406

3.  Liquid-to-gel transition for visual and tactile detection of biological analytes.

Authors:  Tatiana A Fedotova; Dmitry M Kolpashchikov
Journal:  Chem Commun (Camb)       Date:  2017-11-23       Impact factor: 6.222

4.  SPA-LN: a scoring function of ligand-nucleic acid interactions via optimizing both specificity and affinity.

Authors:  Zhiqiang Yan; Jin Wang
Journal:  Nucleic Acids Res       Date:  2017-07-07       Impact factor: 16.971

Review 5.  Oncogenic protein interfaces: small molecules, big challenges.

Authors:  Tracy L Nero; Craig J Morton; Jessica K Holien; Jerome Wielens; Michael W Parker
Journal:  Nat Rev Cancer       Date:  2014-03-13       Impact factor: 60.716

6.  ABCG2 aptamer selectively delivers doxorubicin to drug-resistant breast cancer cells.

Authors:  Shirin Hashemitabar; Rezvan Yazdian-Robati; Maryam Hashemi; Mohammad Ramezani; Khalil Abnous; Fatemeh Kalalinia
Journal:  J Biosci       Date:  2019-06       Impact factor: 1.826

7.  Characterization of an RNA aptamer against HPV-16 L1 virus-like particles.

Authors:  Ana Gabriela Leija-Montoya; María Luisa Benítez-Hess; Julia Dolores Toscano-Garibay; Luis Marat Alvarez-Salas
Journal:  Nucleic Acid Ther       Date:  2014-08-11       Impact factor: 5.486

8.  Nanoporous Glass Integrated in Volumetric Bar-Chart Chip for Point-of-Care Diagnostics of Non-Small Cell Lung Cancer.

Authors:  Ying Li; Jie Xuan; Yujun Song; Wenjin Qi; Bangshun He; Ping Wang; Lidong Qin
Journal:  ACS Nano       Date:  2015-12-28       Impact factor: 15.881

Review 9.  Virus-Derived Peptides for Clinical Applications.

Authors:  Mingying Yang; Kegan Sunderland; Chuanbin Mao
Journal:  Chem Rev       Date:  2017-07-19       Impact factor: 60.622

10.  RAID3--An interleukin-6 receptor-binding aptamer with post-selective modification-resistant affinity.

Authors:  Florian Mittelberger; Cindy Meyer; Georg H Waetzig; Martin Zacharias; Erica Valentini; Dmitri I Svergun; Katharina Berg; Inken Lorenzen; Joachim Grötzinger; Stefan Rose-John; Ulrich Hahn
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.